Thermo Fisher Scientific (TMO-N)

Touches all aspects of bio-pharma industry. For example, helps run pharmaceutical trials, and helps build and design new drugs. Everything you need, such as electron microscopes, to create new drugs and products. 

Weak coming out of Covid, as there was too much inventory in the system. Now primed to see revenue growth reaccelerate. Last time, Trump was favourable to healthcare and biotech. Low multiple relative to its historical average. Yield is 0.3%.

Scores 10/10 in her book. A global leader in scientific devices. Earnings grew double digits in the past 5 years and she expects steady growth to come. They raised EPS guidance from $21.35 to $22.00. There's 17% upside.

Still owns business. Excellent business. Expecting earnings to grow. Ability to grow in USA very good. Slow and steady growth - defensive name. Very good for a long term investor. 

All the tools and services that the healthcare industry needs, so you get diversity with just the one stock. Very well managed. Long-term growth targets are 7-9%. Always improves margins. China is about 8% of revenues, a bit weaker. Biotech funding dried up with higher rates. Inventory destocking. Hopefully, those 3 factors are behind them.

Likes it. Great job improving ROE, pretty stable sales growth. Estimate for 2025 is 11-12% earnings growth. Technically, sets up well.

Benefitted from Covid, but afterwards there was too much inventory. But the PE fell from 30x to 20x, and is exiting the excess and entering a long cycle. Will grow earning 10-15% including by acquisition. Healthcare/pharma/biotech he expects will grow.

It made a buy list today and deserved it. They're starting to see a rebound after Covid. They have a lot of diagnostic equipment that's widely used across healthcare. Shares are earnings are coming out of the doldrums and starting to move up.

World leader, dominates the industry. Not cheap, but solid long-term grower.

Still very positive, especially as spending by pharmaceuticals is getting more robust.

They delivered today a strong earnings and revenue beat as they raised their full-year forecast. Thinks this the last quarter of revenue shrinkage before it gets a major rise in the second half of 2024.

Subdued returns. A leader, critical player in its sector. Stock's lagged due to inventory destocking, higher interest rates, and softer Chinese economy. These issues are largely resolved.

It is the leading company for testing new drugs. It has grown from acquisitions and is now growing at a rate of 5 to7% a year. Buy and hold.

Higher interest rates saw weaker funding in biotech. China had weak demand, though only about 8% of revenues. Still likes it long term for a picks and shovels play.

Avoid TMO because their revenues are flattening. Both trade at a high PE. BDX hasn't done much in share movement. He'd rather pay more for Boston Scientific which performs better.

Not a major growth company, but will grow steady. ~7% top line growth expected to continue. ~10% share price appreciation expected going forward. Will continue to hold in portfolio.